Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA-Reference-Cited by-同舟云学术

Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA

Published:2015-01 Issue:1 Volume:26 Page:113-119
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Krop I.E.,Lin N.U.,Blackwell K.,Guardino E.,Huober J.,Lu M.,Miles D.,Samant M.,Welslau M.,Diéras V.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Reference31 articles.

1. CNS metastases in breast cancer;Lin;J Clin Oncol,2004

2. Metastatic behavior of breast cancer subtypes;Kennecke;J Clin Oncol,2010

3. Breast cancer metastasis to the central nervous system;Weil;Am J Pathol,2005

4. Survival in patients with brain metastases from breast cancer: the importance of HER-2 status;Eichler;Cancer,2008

5. Central nervous system metastases in patients with HER2-positive metastatic breast cancer: incidence, treatment, and survival in patients from registHER;Brufsky;Clin Cancer Res,2011

Cited by 337 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Risk of radionecrosis in HER2-positive breast cancer with brain metastasis receiving trastuzumab emtansine (T-DM1) and brain stereotactic radiosurgery;Radiotherapy and Oncology;2024-10

2. Trastuzumab deruxtecan in HER2-positive advanced breast cancer with or without brain metastases: a phase 3b/4 trial;Nature Medicine;2024-09-13

3. A Pooled Analysis of Trastuzumab Deruxtecan in Patients With HER2-Positive Metastatic Breast Cancer With Brain Metastases;Annals of Oncology;2024-09

4. Long-Term Success With a TDM-1 Biosimilar in Recurrent HER2-Positive Breast Cancer With Multisite Metastases: A Comprehensive Case Study;Cureus;2024-08-16

5. Effectiveness and Safety of Pyrotinib-Based Therapy in the Treatment of HER2-Positive Breast Cancer Patients with Brain Metastases: A Multicenter Real-World Study;Clinical Breast Cancer;2024-08